Clinical Study Of Pemetrexed Plus Platinum Contrasted With EGFR-TKIs As First-line Treatment For Advanced Non-small Cell Lung Cancer

ObjectiveTo pemetrexed combined platinum the treatment and in the treatment of advanced non-small cell lung cancer(NSCLC)effect and toxic reaction aspects comparative analysis,to explore advanced NSCLC how to use the best possible treatment curative effect for patients to obtain the highest income,realize the optimization of treatment effect.MethodsCollection in November 2014 to November 2016 to the second hospital of jilin university confirmed by pathological and clinical data of patients with advanced NSCLC.Statistical accept pemetrexed combined platinum or the treatment received A total of 72 patients with the treatment,the existence of pemetrexed combined platinum(group A),A total of 40 cases with 500 mg/m2 pemetrexed,long A period is three weeks;The treatment there is a total of 32 cases(B)group,the treatment of 250 mg/day,oral,compared two groups after treatment in patients with clinical efficacy and adverse reactions occur.Results1)recent efficient: group A and group B efficient(RR)were 15% and 12.5% respectively,the former is the latter A little higher,but there was no statistically significant difference(p > 0.05);Disease control rates(DCR)in group A was 62.5%,B group was 59.4%,there was no significant difference between groups(p > 0.05).Adverse reactions 2): pemetrexed combined platinum group mainly for gastrointestinal reactions such as vomiting and bone marrow suppression(leukopenia,neutrophil count down),the treatment for the group bulge reaction is rash and diarrhea,two groups of patients with adverse reactions can be tolerated,in comparison,for the treatment group,adverse reaction is lighter pemetrexed combined platinum group,the higher quality of life of patients.Conclusion(1)Pemetrexed plus platinum,or gefitinib in first-line treatment of advanced NSCLC is safe and effective alternative treatment methods.(2)Both pemetrexed plus platinum and oral gefitinib monotherapy in the treatment of advanced NSCLC well tolerated,the toxic reactions can be adjusted,The adverse effects of the gefitinib group were lighter,quality of life could be better.(3)Pemetrexed appears to be more suitable for patients with larger tumor burden and younger age;gefitinib is suitable for EGFR(+),tumor burden is relatively small,older,Hospital resistance patients.(4)In view of the actual economic situation of the affected population in China,pemetrexed is affordable and may be the preferred group for more patients?(5)In view of the evidence of a large number of evidence-based medicine and the benefits of precision treatment,vigorously promote advanced NSCLC for EGFR detection,according to the test results determine the treatment;EGFR positive recommended gefitinib and other TKI treatment.